SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* WINSTON ROY (Last) (First) (Middle) C/O PACIRA BIOSCIENCES, INC. 5401 WEST KENNEDY BOULEVARD, SUITE 890 (Street) TAMPA FL 33609 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [ PCRX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Medical Officer
	3. Date of Earliest Transaction (Month/Day/Year) 06/06/2022
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/06/2022		S		2,099(1)	D	$61.374	44,357	D
Common Stock	06/06/2022		M(2)		6,250	A	$34.375	50,607	D
Common Stock	06/06/2022		S(2)		2,535	D	$60.55(3)	48,072	D
Common Stock	06/06/2022		S(2)		2,300	D	$61.59(4)	45,772	D
Common Stock	06/06/2022		S(2)		1,300	D	$62.43(5)	44,472	D
Common Stock	06/06/2022		S(2)		115	D	$63.4(6)	44,357	D
Common Stock	06/06/2022		S(2)		3,533	D	$60.55(7)	40,824	D
Common Stock	06/06/2022		S(2)		3,650	D	$61.59(8)	37,174	D
Common Stock	06/06/2022		S(2)		1,891	D	$62.48(9)	35,283	D
Common Stock	06/06/2022		S(2)		123	D	$63.69(10)	35,160	D
Common Stock	06/08/2022		A		9,900(11)	A	$0.00	45,060	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$34.375	06/06/2022		M			6,250	(12)	05/02/2028	Common Stock	6,250	$0.00	0	D
Stock Option (Right to Buy)	$59.39	06/08/2022		A		24,800		(13)	06/08/2032	Common Stock	24,800	$0.00	24,800	D

Explanation of Responses:

1. Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

2. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.23 to $61.22, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 3 through 10.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.23 to $62.17, inclusive.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.23 to $62.78, inclusive.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.29 to $64.14, inclusive.

7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.220 to $61.215, inclusive.

8. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.22 to $62.18, inclusive.

9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.200 to $62.935, inclusive.

10. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.60 to $64.06, inclusive.

11. Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

12. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

13. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	06/08/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.